Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology

Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane Morey Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

Original languageEnglish (US)
Pages (from-to)625-657
Number of pages33
JournalArchives of Pathology and Laboratory Medicine
Volume141
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Clinical Pathology
Medical Oncology
Molecular Pathology
Colorectal Neoplasms
Biomarkers
Epidermal Growth Factor Receptor
Guidelines
Therapeutics
Monoclonal Antibodies
Drug Therapy
Mutation
Pathologists
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Molecular biomarkers for the evaluation of colorectal cancer : Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology. / Sepulveda, Antonia R.; Hamilton, Stanley R.; Allegra, Carmen J.; Grody, Wayne; Cushman-Vokoun, Allison M.; Funkhouser, William K.; Kopetz, Scott E.; Lieu, Christopher; Lindor, Noralane Morey; Minsky, Bruce D.; Monzon, Federico A.; Sargent, Daniel J.; Singh, Veena M.; Willis, Joseph; Clark, Jennifer; Colasacco, Carol; Bryan Rumble, R.; Temple-Smolkin, Robyn; Ventura, Christina B.; Nowak, Jan A.

In: Archives of Pathology and Laboratory Medicine, Vol. 141, No. 5, 01.05.2017, p. 625-657.

Research output: Contribution to journalArticle

Sepulveda, AR, Hamilton, SR, Allegra, CJ, Grody, W, Cushman-Vokoun, AM, Funkhouser, WK, Kopetz, SE, Lieu, C, Lindor, NM, Minsky, BD, Monzon, FA, Sargent, DJ, Singh, VM, Willis, J, Clark, J, Colasacco, C, Bryan Rumble, R, Temple-Smolkin, R, Ventura, CB & Nowak, JA 2017, 'Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology', Archives of Pathology and Laboratory Medicine, vol. 141, no. 5, pp. 625-657. https://doi.org/10.5858/arpa.2016-0554CP
Sepulveda, Antonia R. ; Hamilton, Stanley R. ; Allegra, Carmen J. ; Grody, Wayne ; Cushman-Vokoun, Allison M. ; Funkhouser, William K. ; Kopetz, Scott E. ; Lieu, Christopher ; Lindor, Noralane Morey ; Minsky, Bruce D. ; Monzon, Federico A. ; Sargent, Daniel J. ; Singh, Veena M. ; Willis, Joseph ; Clark, Jennifer ; Colasacco, Carol ; Bryan Rumble, R. ; Temple-Smolkin, Robyn ; Ventura, Christina B. ; Nowak, Jan A. / Molecular biomarkers for the evaluation of colorectal cancer : Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology. In: Archives of Pathology and Laboratory Medicine. 2017 ; Vol. 141, No. 5. pp. 625-657.
@article{95816b80a7c2470f8691e2562fdc194e,
title = "Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology",
abstract = "Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.",
author = "Sepulveda, {Antonia R.} and Hamilton, {Stanley R.} and Allegra, {Carmen J.} and Wayne Grody and Cushman-Vokoun, {Allison M.} and Funkhouser, {William K.} and Kopetz, {Scott E.} and Christopher Lieu and Lindor, {Noralane Morey} and Minsky, {Bruce D.} and Monzon, {Federico A.} and Sargent, {Daniel J.} and Singh, {Veena M.} and Joseph Willis and Jennifer Clark and Carol Colasacco and {Bryan Rumble}, R. and Robyn Temple-Smolkin and Ventura, {Christina B.} and Nowak, {Jan A.}",
year = "2017",
month = "5",
day = "1",
doi = "10.5858/arpa.2016-0554CP",
language = "English (US)",
volume = "141",
pages = "625--657",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Molecular biomarkers for the evaluation of colorectal cancer

T2 - Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology

AU - Sepulveda, Antonia R.

AU - Hamilton, Stanley R.

AU - Allegra, Carmen J.

AU - Grody, Wayne

AU - Cushman-Vokoun, Allison M.

AU - Funkhouser, William K.

AU - Kopetz, Scott E.

AU - Lieu, Christopher

AU - Lindor, Noralane Morey

AU - Minsky, Bruce D.

AU - Monzon, Federico A.

AU - Sargent, Daniel J.

AU - Singh, Veena M.

AU - Willis, Joseph

AU - Clark, Jennifer

AU - Colasacco, Carol

AU - Bryan Rumble, R.

AU - Temple-Smolkin, Robyn

AU - Ventura, Christina B.

AU - Nowak, Jan A.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

AB - Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

UR - http://www.scopus.com/inward/record.url?scp=85012091267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012091267&partnerID=8YFLogxK

U2 - 10.5858/arpa.2016-0554CP

DO - 10.5858/arpa.2016-0554CP

M3 - Article

C2 - 28165284

AN - SCOPUS:85012091267

VL - 141

SP - 625

EP - 657

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -